Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China

Table 1 Regimens of direct-acting antivirals for treatment of hepatitis C virus infection

Patients		Genotype 1	Genotype 2	Genotype 3
Chronic hepatitis	Treatment naïve	SOF + LDV for 12 wk	SOF + RBV for 12 wk	SOF + DCV for 12 wk
	Treatment experienced		SOF + RBV for 16-20 wk	SOF + DCV + RBV for 12 wk or 24 wk without RBV
Cirrhosis, compensated or decompensated		SOF + LDV + RBV for 12 wk or 24 wk without RBV	SOF + RBV for 16-20 wk	SOF + DCV + RBV for 24 wk

A fixed dose combination of sofosbuvir (SOF) and ledipasvir was administered once per day. One tablet each of SOF and daclatasvir should be taken daily. Ribavirin was 1000 or 1200 mg/d in patients < 75 kg or ≥ 75 kg, respectively. SOF: Sofosbuvir (400 mg); LDV: Ledipasvir (90 mg); DCV: Daclatasvir (60 mg); RBV: Ribavirin (200 mg).